Alpha particles are composite particles consisting of two protons and two neutrons tightly bound together. They are emitted from the nucleus of some radionuclides during a form of radioactive decay, called alpha-decay. An alpha-particle is identical to the nucleus of a normal (atomic mass four) helium atom i.e. a doubly ionized helium atom. Alpha particles (also termed alpha radiation or alpha rays) was the first nuclear radiation to be discovered, beta particles and gamma rays were identified soon after. Alpha particles are relatively slow and heavy compared with other forms of nuclear radiation. The particles travel at 5 to 7 % of the speed of light or 20,000,000 meters per second and has a mass approximately equivalent to 4 protons. Alpha particles, because they are highly ionizing, are unable to penetrate very far through matter and are brought to rest by a few centimeters of air or less than a tenth of a millimeter of biological tissue. Alpha particles are highly ionizing because of their double positive charge, large mass (compared to a beta particle) and because they are relatively slow. They can cause multiple ionizations within a very small distance. This gives them the potential to do much more biological damage for the same amount of deposited energy. Alpha particles cannot penetrate the normal layer of dead cells on the outside of our skin but can damage the cornea of the eye. Alpha-particle radiation is normally only a safety concern if the radioactive decay occurs from an atom that is already inside the body or a cell. Alpha-particle emitters are particularly dangerous if inhaled, ingested, or if they enter a wound.

Market Dynamics

Leading market players are focused on expanding their therapeutic radioisotope production facilities, which is expected to present attractive growth opportunities for global alpha emitter market, over the forecast period. For instance, on March 01, 2023, NorthStar Medical Radioisotopes, a pharmaceutical company, announced that it has made significant progress in its efforts to offer commercial-scale manufacturing of the rare therapeutic radioisotope actinium-225. A custom-built IBA RhodotronTT 300-HE electron beam accelerator has been delivered to NorthStar’s new Ac-225 production facility in Beloit, Wisconsin, U.S. and installed in the building. This cutting-edge facility, which is a part of NorthStar's expansion plan, will be exclusively used to produce non-carrier added (n.c.a.) Ac-225, in order to ensure scalable, dependable, and environmentally preferable production of Ac-225 for the treatment of patients with cancer and other serious diseases.

Key features of the study:

• This report provides an in-depth analysis of the global alpha emitter market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global alpha emitter market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd, Bayer AG, Bracco, Cardinal Health, Eckert & Ziegle, Fusion Pharmaceuticals, IBA Worldwide, NorthStar Medical Radioisotopes (NMR), Orano Group, Viewpoint Molecular Targeting, RadioMedix, Telix Pharmaceuticals Limited., TerraPower, LLC, NIOWAVE Inc. and IONETIX Corporation.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global alpha emitter market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global alpha emitter market

Detailed Segmentation:

• Global Alpha Emitter Market, By Type of Radionuclide:
  • Radium (Ra-223)
  • Actinium (Ac-225)
  • Lead (Pb-212)
  • Astatine-211
  • Bismuth-213
  • Others
• Global Alpha Emitter Market, By Source:
  • Natural Sources
    • Uranium-238
    • Radium-226
  • Artificially Produced Sources
    • Plutonium
    • Americium
    • Curium
    • Californium
• Global Alpha Emitter Market, By Application:
  • Bone Metastases
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Ovarian Cancer
  • Others
• Global Alpha Emitter Market, By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others
• Global Alpha Emitter Market, By Region:
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Actinium Pharmaceutical Inc.
  • Alpha Tau Medical Ltd
  • Bayer AG
  • Bracco
  • Cardinal Health
  • Eckert & Ziegle
  • Fusion Pharmaceuticals
  • IBA Worldwide
  • NorthStar Medical Radioisotopes (NMR)
  • Orano Group
  • Viewpoint Molecular Targeting
  • RadioMedix
  • Telix Pharmaceuticals Limited.
  • TerraPower, LLC
  • NIOWAVE Inc.
  • IONETIX Corporation.